High Resolution Three-dimensional Maps of the Right Chambers in Patient Diagnosed With Cardiac Amyloidosis

NCT ID: NCT04956965

Last Updated: 2021-07-09

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-08-31
• Study Completion Date: 2022-05-31

Brief Summary

Amyloid heart disease is an accumulation of fibrillar proteins in the extracellular sector of the heart.

Identified on echocardiography as Ventricular hypertrophy. The investigation of a Left Ventricular hypertrophy (LVH) is the most frequent discovery circumstance of amyloid heart disease.

Pathophysiological mechanisms poorly understood, resulting in late diagnosis. Transthyretin amyloid heart disease (CATTR) is the most common form of cardiac amyloidosis in the West Indies due to an abnormally high frequency of the Val122Ile and Val107Ile mutations of the transthyretin gene in this population. Val122Ile and Val107Ile mutated-transthyretin are the substitution of valine for isoleucine at codon 122 of the TTR gene ( V122I) and at codon 107 of the TTR gene (V107I).

Complications of CATTR are functional changes in heart cells or even death due to mechanical abnormalities (loss of contractility and increased wall stiffness cardiac arousal and conduction disturbances).

These disorders result from an electrical abnormality of the heart the reason why the cardiologist performs preventive performance of electrophysiological explorations with EnSite Precision™. It's a registration system used to detect foci of necrosis within the myocardium.

Amyloid deposits are areas devoid of electrical activity. Do they detectable by the EnSite Precision™ recording system ?

Detailed Description

Transthyretin's amyloid heart disease (CATTR) is a rare disease whose frequency is high in the Caribbean's due to a high frequency of Val122Ile, an amyloidosis prone mutation in the Transthyretin gene. The Val122Ile variant might be present in 15 to 20 000 subjects in Martinique, placing them at high risk to develop the CATTR.

CATTR results from the accumulation of amyloid deposits between the intercellular spans, resulting in mechanical cardiac abnormalities, but also in latent excitation or conduction defects: atrial and ventricular hyperexcitability, bundle branch blocks, atrio-ventricular blocks. These abnormalities require systematic electrophysiological studies and if necessary, antiarrythmic medications or pacemaker placement.

Electro-mapping of the cardiac chambers offers high-resolution three-dimensional maps of cardiac electrical activity which has been used recently to detect focal myocardial infarction.

This anatomo-functional imaging, used only once in cardiac amyloidosis, showed a correlation between areas of low voltage of the left atrial myocardium and areas of late gadolinium enhancement, a marker of amyloidosis deposit, found in cardiac MRI.

Conditions

Cardiac Amyloidosis; Cardiac Disease

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Patient free cardiac amyloidosis

Patient with heart disease (related with rhythm disorders or conduction disorders) but free cardiac amyloidosis.

Group Type: ACTIVE_COMPARATOR

Cardiac electro-mapping

Intervention Type: RADIATION

Perform an high-resolution three-dimensional maps of cardiac electrical activity using EnSite Precision system.

Patient with Transthyretin cardiac amyloidosis

Patient with transthyretin cardiac amyloidosis plus heart disease (related with rhythm disorders or conduction disorders).

Group Type: EXPERIMENTAL

Cardiac electro-mapping

Intervention Type: RADIATION

Perform an high-resolution three-dimensional maps of cardiac electrical activity using EnSite Precision system.

Interventions

Cardiac electro-mapping

Perform an high-resolution three-dimensional maps of cardiac electrical activity using EnSite Precision system.

Intervention Type: RADIATION

Eligibility Criteria

Inclusion Criteria

Controls:

• Aged 18 and more
• Have had an echocardiogram within 6 months prior to inclusion
• Have had a cardiac Holter in the 6 months prior to inclusion.
• Informed Consent given

Cases :

• Aged 18 and over
• Presence of cardiac amyloidosis with Transthyretin
• Have had an echocardiogram within 6 months prior to inclusion
• Have had a cardiac Holter monitoring in the 6 months prior to inclusion.
• Informed Consent given

Exclusion Criteria

Controls

• Known case of amyloidosis in the immediate family
• Patient known to have amyloidosis
• Left ventricular wall thickness greater than or equal to 14 mm
• Hyperechogenicity of the left ventricular walls
• Cardiac disease which may affect electro-anatomic mapping: Right ventricular dysplasia, myocardial infarction, congenital heart disease.
• Contraindication such as pregnancy to radiological exams
• Presence of an anomaly of the vena cava
• Presence of intracavitary thrombus at cardiac echocardiography
• Patients with a pacemaker

Cases

• Cardiac disease which may affect electro-anatomic mapping: Right ventricular dysplasia, myocardial infarction, congenital heart disease.
• Contraindication such as pregnancy to radiological exams
• Presence of an anomaly of the vena cava
• Presence of intracavitary thrombus at cardiac echocardiography

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

GIRCI SOHO

OTHER

Sponsor Role: collaborator

University Hospital Center of Martinique

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jocelyn INAMO, MD, PhD

Role: STUDY_DIRECTOR

CHU de Martinique

Fabrice DEMONIERE, MD

Role: PRINCIPAL_INVESTIGATOR

CHU de Martinique

Locations

Centre Hospitalier Universitaire de Fort-de-France

Fort-de-France, , Martinique

Countries

Martinique

Central Contacts

Jocelyne CRASPAG, MSc

Role: CONTACT

jocelyne.craspag@chu-martinique.fr

+596596592698

Fabrice DEMONIERE, MD

Role: CONTACT

fabrice.demoniere@chu-martinique.fr

+596596306490

Facility Contacts

Fabrice DEMONIERE, MD

Role: primary

fabrice.demoniere@chu-martinique.fr

+596596306490

Jocelyne CRASPAG, MSc

Role: backup

jocelyne.craspag@chu-martinique.fr

+596596592698

References

Khairy LT, Barin R, Demoniere F, Villemaire C, Billo MJ, Tardif JC, Macle L, Khairy P. Heart Rate Response in Spectators of the Montreal Canadiens Hockey Team. Can J Cardiol. 2017 Dec;33(12):1633-1638. doi: 10.1016/j.cjca.2017.08.002. Epub 2017 Oct 5.

Reference Type: RESULT

PMID: 28987521 (View on PubMed)

Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A, Macle L, Daoud EG, Calkins H, Hall B, Reddy V, Augello G, Reynolds MR, Vinekar C, Liu CY, Berry SM, Berry DA; ThermoCool AF Trial Investigators. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA. 2010 Jan 27;303(4):333-40. doi: 10.1001/jama.2009.2029.

Reference Type: RESULT

PMID: 20103757 (View on PubMed)

Parent F, Bachir D, Inamo J, Lionnet F, Driss F, Loko G, Habibi A, Bennani S, Savale L, Adnot S, Maitre B, Yaici A, Hajji L, O'Callaghan DS, Clerson P, Girot R, Galacteros F, Simonneau G. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med. 2011 Jul 7;365(1):44-53. doi: 10.1056/NEJMoa1005565.

Reference Type: RESULT

PMID: 21732836 (View on PubMed)

Oliveira Da Silva L, Fabre J, Monfort A, Villeret J, Citony I, Cohen-Tenoudji P, Lebbadi M, Martin D, Molinie V, Inamo J. 'Green Apple' Heart Failure. West Indian Med J. 2014 Jul 3;63(6):673-5. doi: 10.7727/wimj.2013.255. Epub 2014 Jun 25.

Reference Type: RESULT

PMID: 25803389 (View on PubMed)

Other Identifiers

19_RIPH3-03

Identifier Type: -

Identifier Source: org_study_id